{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"10300","value":"9330"},{"groupId":"OG001","spread":"10400","value":"20000"},{"groupId":"OG003","value":"16100"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"133"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"description":"Results for this outcome measure was reported for Part 2 and Part 3 combined.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with advanced relapsed or refractory lymphomas received TTI-621 0.1 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG000","title":"Part 2 and 3 Combined: 0.1 mg/kg"},{"description":"Participants with advanced relapsed or refractory lymphomas received TTI-621 0.2 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG001","title":"Part 2 and 3 Combined: 0.2 mg/kg"},{"description":"Participants with advanced relapsed or refractory lymphomas received TTI-621 0.3 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG002","title":"Part 2 and 3 Combined: 0.3 mg/kg"},{"description":"Participants with advanced relapsed or refractory lymphomas received TTI-621 0.4 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG003","title":"Part 2 and 3 Combined: 0.4 mg/kg"},{"description":"Participants with advanced relapsed or refractory CTCL received TTI-621 0.5 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG004","title":"Part 2 and 3 Combined: 0.5 mg/kg"}],"paramType":"MEAN","populationDescription":"PK -evaluable set included treated participants with adequate blood sampling to estimate at least one PK parameter. Here, \"Number of participants analyzed\" signifies number of evaluable participants for this outcome measure. Data for only those arms \\[according to dose\\] are reported for this outcome measure which had any evaluable participants.","reportingStatus":"POSTED","timeFrame":"Part 2 and 3: Pre-dose, end of infusion (EOI), 2, 4, 24, 72, 168 hours post dose on Week 1","title":"Part 2 and 3 Combined: Area Under the Plasma Concentration Time Curve From Time Zero to 168 (AUC[0-168]) of TTI-621","type":"SECONDARY","unitOfMeasure":"Nanogram*hour per milliliter"}